Immunotherapy used with chemotherapy or on its own is a better first-line treatment for people with head and neck cancer that has returned than standard aggressive chemotherapy, new clinical trial results show.

A weight loss drug available over the counter in the UK could help women with treatment-resistant ovarian cancer respond to chemotherapy again, a new study suggests.

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.